Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
KRAS in the clinic and conference

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.10.16
Views: 1575

Dr Ana Vivancos - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Dr Vivancos meets with ecancertv at ESMO 2016 to discuss how her lab is targeting KRAS mutations, with liquid biopsies guiding research.

She discusses clinical practice, working with lung adenocarcinomas, metastatic colorectal cancer and pancreatic cancer, and the opportunities of collaboration and professional development through the conference.

Considering the news from ESMO so far, Dr Vivancos anticipates novel biomarkers and immunotherapy having a significant influence over future standards of care.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation